Drug Inflammation;Pain

Velsipity

Payments companies reported to CMS as associated with Velsipity. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.8Massociated payments (2023-2025)

11,322clinicians with associated payments

6companies reporting

By year

2023 $414K

2024 $2.6M

2025 $1.8M

Payments reported as associated with Velsipity, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $3.5M

Family $262K

Physician Assistant $175K

Internal Medicine $93K

Medical $86K

Anatomic Pathology & Clinical Pathology $79K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Velsipity

These are the largest totals companies reported as associated with Velsipity. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Marla Dubinsky	New York, NY		$173,299.90
Georges Catinis	Metairie, LA	Gastroenterology (Internal Medicine)	$121,634.03
Michael Chiorean	Issaquah, WA	Gastroenterology (Internal Medicine)	$101,571.32
David Rubin	Chicago, IL	Gastroenterology (Internal Medicine)	$94,606.07
Douglas Nguyen	Mission Viejo, CA	Gastroenterology (Internal Medicine)	$82,069.23
Reetesh Pai	Palo Alto, CA	Anatomic Pathology & Clinical Pathology	$78,400.00
Zachary Borman	Chevy Chase, MD	Gastroenterology (Internal Medicine)	$77,894.04
Larry Clark	Lynchburg, VA	Gastroenterology (Internal Medicine)	$77,526.97
Arthur Kornbluth	New York, NY	Gastroenterology (Internal Medicine)	$74,926.66
Ronen Arai	Coral Springs, FL	Gastroenterology (Internal Medicine)	$73,718.56

Prescribed Velsipity?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.